Navigation Links
Feinstein Institute researchers identify brain network

Manhassett, NY Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.

Parkinson's disease is the second most common neurodegenerative disease in the US. Those who suffer from Parkinson's disease most often experience tremors, slowness of movement (bradykinesia), rigidity, and impaired balance and coordination. Patients may have difficulty walking, talking or completing simple daily tasks. They may also experience depression and difficulty sleeping due to the disease. The current standard for diagnosis of Parkinson's disease relies on a skilled healthcare professional, usually an experienced neurologist, to determine through clinical examination that someone has it. There currently is no cure for Parkinson's disease, but medications can improve symptoms.

A team of researchers at the Feinstein Institute's Center for Neurosciences, led by David Eidelberg, MD, has developed a method to identify brain patterns that are abnormal or indicate disease using imaging techniques. To date, this approach has been used successfully to identify specific networks in the brain that indicate a patient has or is at risk for Parkinson's disease and other neurodegenerative disorders.

"One of the major challenges in developing new treatments for neurodegenerative disorders such as Parkinson's disease is that it is common for patients participating in clinical trials to experience a placebo or sham effect," noted Dr. Eidelberg. "When patients involved in a clinical trial commonly experience benefits from placebo, it's difficult for researchers to identify if the treatment being studied is effective. In a new study conducted by my colleagues and myself, we have used a new image-based strategy to identify and measure placebo effects in brain disorder clinical trials."

In the current study, the researchers used their network mapping technique to identify specific brain circuits underlying the response to sham surgery in Parkinson's disease patients participating in a gene therapy trial. The expression of this network measured under blinded conditions correlated with the sham subjects' clinical outcome; the network changes were reversed when the subjects learned of their sham treatment status. Finally, an individual subject's network expression value measured before the treatment predicted his/her subsequent blinded response to sham treatment. This suggests that this novel image-based measure of the sham-related network can help to reduce the number of subjects assigned to sham treatment in randomized clinical trials for brain disorders by excluding those subjects who are more likely to display placebo effects under blinded conditions.

Contact: Emily Ng
North Shore-Long Island Jewish (LIJ) Health System

Related medicine news :

1. Feinstein Institute to receive grant to improve schizophrenia treatment
2. Feinstein Institute to Receive Grant from Centers for Medicare & Medicaid Services to Improve Schizophrenia Treatment
3. Feinstein Institute researchers discover that bean used in Chinese food could protect against sepsis
4. Feinstein announces submission of new drug application for diagnosing parkinsonian syndromes
5. Feinstein Institute researchers discover plant derivative
6. A Feinstein Institute for Medical Research Study Shows Early Cognitive Problems among Those Who Eventually Get Alzheimer's
7. Feinstein Institute Scientist Wins Crafoord Award from Royal Swedish Academy of Sciences for Arthritis Research
8. Feinstein Institute Researcher provides insight into osteoarthritis
9. North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week
10. North Shore-LIJ's Feinstein Institute Hosts Academic Commencement and Convocation
11. Feinstein Institute, Hofstra North Shore-LIJ School of Medicine at 36th Annual Conference on Shock
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Dr. Paul Vitenas, one of the top cosmetic surgeons ... magazine as the Best Single Physician Practice in the nation. Dr. Vitenas and his ... honored by the industry publication. , Dr. Vitenas said he was very honored ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation claim ... of hospital and nonhospital care, according to a recent study by the Workers Compensation ... Edition , found medical payments per claim with more than seven days of lost ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... amputations in the United States. Podiatrists are well aware that psychology-based patient non-compliance ... behaviors) are often catastrophic contributors to diseases of the diabetic foot. The ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: ... of chronic pain, announced today that the company will present ... held December 1-3 at the Luxe Sunset Boulevard Hotel in ... , CEO of Relmada Therapeutics, will present on Thursday, December ... . Please register at least 10 minutes ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology: